Comparative Muscle Tolerability of Different Types and Intensities of Statins: A Network Meta-Analysis of Double-Blind Randomized Controlled Trials
- 30 November 2022
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (3) , 459-469
Abstract
Purpose The benefits of statins for ischemic cardio-cerebrovascular diseases are well known. However, concerns around muscle adverse events still exist. We therefore aimed to compare the muscle safety of individual statins in adults. Methods PubMed, Embase, Cochrane Central Register of Controlled Trials and Web of Science were searched to include double-blind randomized controlled trials (RCTs) comparing one statin with another or with control treatment. Pairwise meta-analyses and network meta-analyses were undertaken with Stata 14.0 software. Relative risk (RR) with 95% confidence intervals (CIs) was adopted for each outcome. Results A total of 83 RCTs were included. In the pairwise meta-analysis, statins were significantly associated with only a slight increase in muscle symptoms compared with control (RR=1.05; 95% CI=1.01–1.09). In the drug-level network meta-analyses, no statistically significant difference was found between individual statins in the incidence of muscle symptoms, myalgia, myopathy, rhabdomyolysis, creatine kinase (CK) >10 times the upper limit of normal (ULN) or discontinuation due to muscle adverse events. In the dose-level network meta-analyses, there were no statistically significant dose-dependent effects on any outcomes except that moderate-intensity statins had a higher incidence of muscle symptoms than control (RR=1.13; 95% CI=1.01–1.27). Moderate simvastatin (RR=6.57; 95% CI=1.26–34.41) and moderate pravastatin (RR=5.96; 95% CI=1.00–35.44) had a statistically significantly higher incidence of CK >10×ULN compared with moderate atorvastatin. Lipophilic statins and statins metabolized by liver cytochrome P450 3A4 were not associated with an increased risk of muscle adverse events. Conclusion Statins may be generally safe on muscle. Moderate atorvastatin may be superior to equivalent simvastatin and pravastatin in muscle tolerability.Keywords
Funding Information
- National Natural Science Foundation of China (81901425)
This publication has 52 references indexed in Scilit:
- Effects of Aggressive Statin Therapy on Patients With Coronary Saphenous Vein Bypass Grafts: A Systematic Review and Meta-Analysis of Randomized, Controlled TrialsClinical Therapeutics, 2013
- Evaluation of inconsistency in networks of interventionsInternational Journal of Epidemiology, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Atorvastatin: safety and tolerabilityExpert Opinion on Drug Safety, 2010
- The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trialsCanadian Medical Association Journal, 2008
- Pleiotropic effects of statin therapy: molecular mechanisms and clinical resultsTrends in Molecular Medicine, 2008
- Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trialsHeart, 2007
- Statin-related adverse events: A meta-analysisClinical Therapeutics, 2006
- Early Time to Benefit with Intensive Statin Treatment: Could It Be the Pleiotropic Effects?The American Journal of Cardiology, 2005
- Concomitant use of cytochrome P450 3A4 inhibitors and simvastatinThe American Journal of Cardiology, 1999